Sensitivity for colorectal
cancer is 96.08%1.*

Sensitivity for advanced
precancerous lesions is 52.5%1.*

* Advanced precancerous lesions including advanced adenoma (tubular adenoma measuring ≥ 1 cm in greatest diameter, or adenoma with significant villous features), large serrated lesions or high-grade dysplasia.

ColoTect consists of 4 kits

Testing Reagents

  • 01.Stool Sample Collection Kit
  • 02.Stool DNA Isolation Kit
  • 03.Sample Pretreatment Kit for Methylation Detection
  • 04.Combined Detection Kit for Human Genes Methylation and Fecal Occult Blood

Product Advantages

Sample collection process is designed with privacy and convenience in mind. Customers can collect stool samples in the comfort of their homes and mail samples back to the processing laboratories.

Non-invasive and painless test uses stool samples to perform early detection of colorectal cancer and does not require bowel preparation.

The multi-biomarker DNA and FIT combined testing technology increases rate of detection of colorectal cancer and pre-cancerous lesions, offering ideal performance for colorectal cancer early screening.

BGI can provide entire end-to-end testing infrastructure.

Features of ColoTect

Licensing and Registration

  • • CE-IVDD
  • •CE-IVDR
Clinical validation of Colotect and Publications
Data security and pravicy protection

Data security and privacy protection

Data protection is important in health-related data. And BGI checks for our data security through independent committees.

Your test results will only be sent to you or your attending physician if requested.

Videos

References:

  • 1.In early 2023, BGI plans to release case-control data generated internally for an enhanced version of COLOTECT 3.0 at 2023 ASCO Gastrointestinal Cancers Symposium （Abstract #392806 ）. COLOTECT 3.0 had a 96.08 percent sensitivity to detect CRC and an 88.7percent specificity for gauging non-advanced adenomas. In detecting patients with advanced precancerous lesions, sensitivity was 52.5 percent for COLOTECT 3.0, which was found superior to FIT with a sensitivity of 22.5 percent.

Intended Use and Important Risk Information:

The Combined Detection Kit for Human Gene Methylation and Fecal Occult Blood is a non-invasive in vitro diagnostic (IVD) assay for qualitative detection of certain genes’ methylation and fecal hemoglobin from human stool specimens. The kit is intended to be used for screening colorectal cancer in the general population. A positive test result indicates that the subject may have colorectal cancer and/or advanced adenoma, and further colonoscopy is required; on the contrary, a negative test result indicates that the subject has a low possibility of colorectal cancer and/or advanced adenoma, however, the risk of disease cannot be completely ruled out. The product is applicable to all people between the ages of 40 to 75 who need colorectal cancer screening.

This product cannot replace colonoscopy, and the test results of this kit should not be used as the only basis for clinical diagnosis. Clinicians should comprehensively judge the results based on the patient's condition and other laboratory indicators. CE marked.